The MRC-MATURA TranSMART infrastructure enables inte­­grated analysis towards the identification of biomarker signatures that will help researchers and clinicians better understand the different responses to biologic drugs that are seen in the clinic, ultimately offering better and more personalised treatment to those affected by rheumatoid arthritis.
The MRC-MATURA TranSMART platform enables researchers to:

• Develop, test and refine research hypotheses
• Search multiple data sets for potential drug targets, pathways and biomarkers
• Compare data from proteomics, metabolomics and other “omics” studies
• Contrast patterns of gene expression in healthy and diseased individuals and tissue samples
• Investigate correlations between genotype and phenotype in clinical trial data
• Study genetic and environmental factors involved in RA
• Display data visually using a graphical interface
• Stratify clinical data into molecular subtypes of RA disease and drug response
• Collaborate across the academic and industrial partnership of the MATURA consortium

The TranSMART community
The TranSMART platform, which was originally developed and open sourced by our industrial partner, Janssen, is now widely used internationally for translational research (http://transmartfoundation.org/). The MRC-MATURA TranSMART has itself been developed in close collaboration with the MRC-PSORT and the MRC-RA-MAP consortium in collaboration with the Innovative Medicines Initiative (IMI) project European Translational Information and Knowledge Management Services (eTRIKS).

For more information on TranSMART contact Dr Michael Barnes: m.r.barnes@qmul.ac.uk